DAVID HAGEMANN: Open Payments
NPI 1881675619 · ROSEVILLE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,345 in 118 payments from 20 companies in 2025. Trend: 2023 $2,486 · 2024 $2,499 · 2025 $2,345
Food & beverage: $2,345
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 11 | $326 |
| ABBVIE INC. | 17 | $262 |
| Incyte Corporation | 10 | $232 |
| LEO Pharma Inc. | 12 | $213 |
| E.R. Squibb & Sons, L.L.C. | 11 | $188 |
| Lilly USA, LLC | 9 | $161 |
| Galderma Laboratories, L.P. | 10 | $159 |
| Regeneron Healthcare Solutions, Inc. | 6 | $145 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 8 | $139 |
| Novartis Pharmaceuticals Corporation | 3 | $75 |
Products named: DUPIXENT, OPZELURA, Sotyktu, ADBRY, NEMLUVIO, TALTZ, SKYRIZI, RINVOQ.
Industry payments across CA — which companies pay providers there.
